Regeneron Re-Rated 50% on a Promise It Has Been Making for Three Years
Q3 was a blowout — but the durable news is a reset in Sanofi economics and a liver-fat number that finally gives the pipeline skeptics a denominator.
REGN · Earnings Call · 2026-10-30
The print, and the tape that got there first
Regeneron's stock is up roughly 50% in ninety trading days — one clean, unbroken leg on the price tape — and it did that before this quarter printed. The company reported on October 30 with shares still about 23% below the August 2024 peak of $1,201.76, so the move is a partial repair of a two-year drawdown, not a fresh high. That sequencing matters: the market had already begun voting that Regeneron was no longer an EYLEA-decline story before management had to prove it. Then management proved it. Total revenue rose 36% to $5.1 billion and non-GAAP diluted EPS rose 70% to $20.07. “This marks our third consecutive quarter of double digit growth on both the top and bottom lines.” — Leonard S. Schleifer, Co-Founder, President and Chief Executive Officer · 2026-10-30 Dupixent hit a record $6.5 billion in global sales (+35% constant currency), EYLEA HD a record ~$700 million (+62%), Libtayo a record $550 million (+51%). Three brands, three all-time highs, in the same quarter. Note the data lag: the fundamentals block here runs only through the June quarter — $4.29 billion of revenue at a 35.6% operating margin, down 5.7 points year over year. The blowout quarter is not in the numbers yet. That gap between the transcript and the timeseries is exactly where the story lives.The Sanofi reset is the actual news
Buried in the CFO's section is the most consequential structural fact of the quarter, and it is not a growth rate. Sanofi collaboration revenue reached $2.7 billion, including $2.6 billion of profit share, up 77%. The reason: “we recorded our full share of collaboration profits for the first time.” — Christopher R. Fenimore, Senior Vice President, Interim Chief Financial Officer and Treasurer · 2026-10-30 The development balance — the funding drag that had suppressed Regeneron's economics on its own biggest asset for years — was repaid in the second quarter. That is a permanent step-change in the shape of the income statement, and it arrives alongside a rebuilt alliance with Sanofi: four fully human long-acting antibodies and bispecifics, costs and profits split 50/50 with no development balance, and a $1 billion upfront payment to be booked in Q4. The share of collaboration profit line stops being a legacy accounting artifact and becomes a clean, symmetric venture. Len Schleifer framed it as a reversal of posture — Regeneron as historically a net out-licenser of innovation, now with the balance sheet to bring things in.New vocabulary: liver fat, POTS, ovarian
The keyword rotation this quarter is unusually sharp. At the top of the company's own language sits liver fat, liver disease and a gene name that did not exist in prior calls: CIDEB, discovered inside the Regeneron Genetics Center. The data, from 40 participants, were quantified for the first time:This was telegraphed — in July, Salveen Richter asked “You'll be presenting data from one of your siRNA programs in MASH this year” — Salveen Richter, Analyst · 2026-07-30 — so the surprise is magnitude and speed, not existence. The same is true of Ovarian cancer: ubamatamab delivered roughly a 70% objective response rate in advanced low-grade serous disease versus sub-15% for chemotherapy, and Regeneron is enrolling a registrational cohort. Genuinely new is POTS (postural orthostatic tachycardia syndrome), where a single dose of REGN751 produced sustained improvements, with a potentially pivotal study planned for the first half of next year. And the near-term catalyst is Myasthenia Gravis: cemdisiran's November PDUFA, pitched on subcutaneous dosing just four times a year — the same long acting argument now carrying the entire next-generation immunology franchise. The commercial organization already calls on nearly every specialty these assets need.a single dose was well tolerated and reduced liver fat by approximately 70% on average from baseline in just 12 weeks... This effect was durable through 24 weeks of follow-up
What stopped being said
Three themes went quiet, and silence is data. First, fianlimab. Across the January, April and July calls, analysts pressed repeatedly on the LAG-3 program's hazard ratio and event rate in metastatic melanoma. In July, George Yancopoulos conceded “we just missed on our primary endpoint.” — George Yancopoulos, President and Chief Scientific Officer · 2026-07-30 On this call: not a single mention, in prepared remarks or Q&A. The pipeline slide has moved on. Second, obesity rhetoric. patients with obesity ranked near the top of the company's vocabulary in the June quarter; this quarter the closest surviving phrase is a mid-ranked "metabolic disease," and olatorepatide appears mainly as a 2027 trial-start logistics item. The metabolic emphasis has migrated from weight loss to the liver — a different, less crowded, and arguably more defensible claim. Third, EYLEA itself. Combined U.S. franchise sales fell 1%, with legacy EYLEA down 41% and HD up 62%. Management's framing is now entirely about the prefilled syringe as the next "leg of the stool" — the same promise made in the July Q&A, when Schleifer said the company was working with "more than two" contract manufacturers. The syringe slipping again would be the one thing that breaks this narrative.The bill arrives in 2027
Here is the tension worth holding. EPS grew 70%, but the CFO immediately flagged that “we currently expect 2027 R&D expense to increase by a mid teens percentage compared with 2026,” — Christopher R. Fenimore, Senior Vice President, Interim Chief Financial Officer and Treasurer · 2026-10-30 plus 100–200 basis points of tax-rate pressure. R&D of $1.6 billion against $4.29 billion of revenue is a 38% R&D intensity in the last filed quarter, and free cash flow less stock comp was only $330 million, a 7.7% margin. The $21.2 billion effective net cash funds it — $2.3 billion of buybacks year-to-date, ~$3 billion planned for the full year — but the 2027 spend step-up is real, and it lands just as the market has started paying for the pipeline. That is why the perennial analyst complaint resurfaced yet again. In April, David Risinger put it bluntly:Yancopoulos's answer then — “past performance should be the strongest indicator of future performance” — George Yancopoulos, President and Chief Scientific Officer · 2026-04-29 — is the same rhetorical move as every "game changing" superlative on this call. What is different is that this quarter came with numbers instead of adjectives, and the stock had already begun to believe it. On business development, the posture is unchanged and unapologetic: Schleifer's July line, “I don't think I expressed an aversion to M&A. I think I expressed an aversion to overpaying” — Leonard Schleifer, President and Chief Executive Officer · 2026-07-30 is restated here as open to "any and all opportunities at all stages," with valuation discipline as the only filter.Regeneron spends aggressively on R&D, but the investment community lacks confidence that the company's candidates will move the needle commercially